Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04442126 · OUTCOME

Assessment of the Frequency of Specific Anti-drug Antibodies to NM21-1480

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From baseline to up to 12 weeks post last dose, up to 48 weeks.

Analysis population: A patient is considered positive if they are positive at any scheduled or unscheduled post-baseline assessment.

Groups in this outcome

Part A Dose Level 1 NM21-1480-Q2W 0.15mg

Part A Dose Level 1 NM21-1480-Q2W 0.15mg

Part A Dose Level 2 NM21-1480-Q2W 1.5mg

Part A Dose Level 2 NM21-1480-Q2W 1.5mg

Part A Dose Level 3 NM21-1480-Q2W 8mg

Part A Dose Level 3 NM21-1480-Q2W 8mg

Part A Dose Level 4 NM21-1480-Q2W 24mg

Part A Dose Level 4 NM21-1480-Q2W 24mg

Part A Dose Level 5 NM21-1480-Q2W 80mg

Part A Dose Level 5 NM21-1480-Q2W 80mg

Part A Dose Level 6 NM21-1480-Q2W 240mg

Part A Dose Level 6 NM21-1480-Q2W 240mg

Part A Dose Level 7 NM21-1480-Q2W 800mg

Part A Dose Level 7 NM21-1480-Q2W 800mg

Part A2 NM21-1480-Q2W 1400mg

Part A2 NM21-1480-Q2W 1400mg

Part B NM21-1480-Q2W 800mg

Part B NM21-1480-Q2W 800mg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A Dose Level 1 NM21-1480-Q2W 0.15mg1
Part A Dose Level 2 NM21-1480-Q2W 1.5mg1
Part A Dose Level 3 NM21-1480-Q2W 8mg3
Part A Dose Level 4 NM21-1480-Q2W 24mg3
Part A Dose Level 5 NM21-1480-Q2W 80mg6
Part A Dose Level 6 NM21-1480-Q2W 240mg3
Part A Dose Level 7 NM21-1480-Q2W 800mg9
Part A2 NM21-1480-Q2W 1400mg5
Part B NM21-1480-Q2W 800mg21

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part A Dose Level 1 NM21-1480-Q2W 0.15mg1Not reportedNot reportedNot reportedNot reported
Part A Dose Level 2 NM21-1480-Q2W 1.5mg1Not reportedNot reportedNot reportedNot reported
Part A Dose Level 3 NM21-1480-Q2W 8mg2Not reportedNot reportedNot reportedNot reported
Part A Dose Level 4 NM21-1480-Q2W 24mg3Not reportedNot reportedNot reportedNot reported
Part A Dose Level 5 NM21-1480-Q2W 80mg5Not reportedNot reportedNot reportedNot reported
Part A Dose Level 6 NM21-1480-Q2W 240mg3Not reportedNot reportedNot reportedNot reported
Part A Dose Level 7 NM21-1480-Q2W 800mg6Not reportedNot reportedNot reportedNot reported
Part A2 NM21-1480-Q2W 1400mg1Not reportedNot reportedNot reportedNot reported
Part B NM21-1480-Q2W 800mg14Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        2
      4. group Id
        OG003
        value
        3
      5. group Id
        OG004
        value
        5
      6. group Id
        OG005
        value
        3
      7. group Id
        OG006
        value
        6
      8. group Id
        OG007
        value
        1
      9. group Id
        OG008
        value
        14
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      1
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      3
    5. group Id
      OG004
      value
      6
    6. group Id
      OG005
      value
      3
    7. group Id
      OG006
      value
      9
    8. group Id
      OG007
      value
      5
    9. group Id
      OG008
      value
      21
    units
    Participants
groups
  1. description
    Part A Dose Level 1 NM21-1480-Q2W 0.15mg
    id
    OG000
    title
    Part A Dose Level 1 NM21-1480-Q2W 0.15mg
  2. description
    Part A Dose Level 2 NM21-1480-Q2W 1.5mg
    id
    OG001
    title
    Part A Dose Level 2 NM21-1480-Q2W 1.5mg
  3. description
    Part A Dose Level 3 NM21-1480-Q2W 8mg
    id
    OG002
    title
    Part A Dose Level 3 NM21-1480-Q2W 8mg
  4. description
    Part A Dose Level 4 NM21-1480-Q2W 24mg
    id
    OG003
    title
    Part A Dose Level 4 NM21-1480-Q2W 24mg
  5. description
    Part A Dose Level 5 NM21-1480-Q2W 80mg
    id
    OG004
    title
    Part A Dose Level 5 NM21-1480-Q2W 80mg
  6. description
    Part A Dose Level 6 NM21-1480-Q2W 240mg
    id
    OG005
    title
    Part A Dose Level 6 NM21-1480-Q2W 240mg
  7. description
    Part A Dose Level 7 NM21-1480-Q2W 800mg
    id
    OG006
    title
    Part A Dose Level 7 NM21-1480-Q2W 800mg
  8. description
    Part A2 NM21-1480-Q2W 1400mg
    id
    OG007
    title
    Part A2 NM21-1480-Q2W 1400mg
  9. description
    Part B NM21-1480-Q2W 800mg
    id
    OG008
    title
    Part B NM21-1480-Q2W 800mg
param Type
COUNT_OF_PARTICIPANTS
population Description
A patient is considered positive if they are positive at any scheduled or unscheduled post-baseline assessment.
reporting Status
POSTED
time Frame
From baseline to up to 12 weeks post last dose, up to 48 weeks.
title
Assessment of the Frequency of Specific Anti-drug Antibodies to NM21-1480
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice